Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMD-1111
- Development stage
- Preclinical
- Lead developer
- BiologicsMD
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
BMD-1111 is a targeted therapeutic developed by BiologicsMD, Inc. It is a recombinant fusion protein composed of an Active Domain, which acts as a parathyroid hormone agonist, and a Binding Domain that specifically targets and binds to type I triple-helical collagen. This design allows for the localized activation of the PTH/PTHrP receptor within bone tissue, leading to a sustained therapeutic response with minimal off-target effects, such as hypercalcemia. Preclinical studies have demonstrated its efficacy in promoting bone repair, particularly in models of post-menopausal osteoporosis, with a single subcutaneous injection providing superior results compared to daily administration of teriparatide.
- Other names
- PTH-CBD
02
Targets
COL1 (Collagen type I)PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on BMD-1111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMD-1111.